Research programme: small molecule therapeutics - Third Harmonic Bio
Latest Information Update: 11 Dec 2023
Price :
$50 *
At a glance
- Originator Third Harmonic Bio
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders; Respiration disorders; Skin disorders
Most Recent Events
- 11 Dec 2023 Preclinical trials in Gastrointestinal disorders in USA (PO) before December 2023 (Third Harmonic Bio pipeline, December 2023)
- 25 May 2023 Preclinical trials in Respiration disorders in USA (PO) (Third Harmonic Bio pipeline - May 2023)
- 25 May 2023 Preclinical trials in Skin disorders in USA (PO) (Third Harmonic Bio pipeline - May 2023)